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Abstract
Toward Controlling Cardiac Tissue Pacing Using Modified mRNA
By
Yicheng Zhao
Master of Science in Biomedical Engineering
Washington University in St. Louis, 2020
Research Advisor: Professor Nathaniel Huebsch

Arrhythmia is a common heart disease that happens when the heart is beating too fast, too slow,
or irregularly. To study the mechanisms and treatments of this disease, it is important to acutely
control the beating rate of the model as it will help distinguish the contribution of different
potassium currents and drug-induced action potential in cardiomyocytes. The current method of
tissue pacing, electrical pacing, causes contamination and corrosive damage to tissues, thus the
tissues fail to be used repeatedly or in future studies. In this study, red-shifted channelrhodopsin
(ReaChR) is applied as a non-chemical means to control the beating rate. ReaChR is a light-gated
ion channel that opens and allows potassium to enter cardiomyocytes when excited by red lights.
To deliver ReaChR into micro tissues, modified mRNA is chosen because of its higher transfection
rate comparing to the plasmid, and lower cell toxicity comparing to the virus. Reducible polycation
(RPC) is synthesized and used as transfection reagent to acquire a better transfection rate and
modifiable structure. The results show successful modified mRNA synthesis and enhanced
transfection efficiency with modified mRNA comparing to plasmid in both cells and tissues. The
improved transfection efficiency of modified mRNA into iPSC-derived cardiomyocytes and iPSCderived micro heart muscle using RPC is achieved. The results presented in this thesis demonstrate
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the potential of using modified mRNA to control the beating rate of the tissue and eventually
control other physiological properties in cells.

1
Chapter 1: Introduction
Arrhythmia is a common heart disease that happens when the heart is beating too fast, too slow,
or irregularly (National Heart Lung and Blood Institute). Over 2.2 million Americans are suffering
from arrhythmia, and it may lead to cardiac arrest, stroke, or even sudden death (American Heart
Association, 2016, Sep 30b; Health Engine, 2004, Sep 15). Some previous studies have shown that
arrhythmia is caused by gene mutations and triggered by the increased mechanical loading of
cardiac muscle, which can happen during intense exercise (Herren, Gerber, & Duru, 2009; La
Gerche, 2015). Current medications include calcium-channel blocker, beta blocker and
anticoagulant (American Heart Association, 2016, Sep 30a). However, some of those drugs have
unstable performance in different patients (Krikler, Harris, & Rowland, 1982). Therefore, further
study on the mechanisms of arrhythmia and the effects of different medications on the phenotypes
is needed.

Acutely controlling the beating rate of cardiac tissue allows the characterization of the conduction
velocity, which is a critical factor affecting arrhythmia. It is also a crucial aspect of distinguishing
the contribution of different potassium currents and drug-induced action potential in
cardiomyocytes (La Gerche et al., 2012). In general, to study the chronic effect of specific drugs
on cardiomyocytes and cardiac tissue, and to avoid the interference factors from mechanical
environment, adrenergic stimulation, and other physiological signaling, it is essential to have a
non-chemical means of controlling the beat rate of cardiac tissue.

Currently, the common method is electrical pacing. Although the electrical pacing can be used to
induce the maturation of iPSC-derived cardiomyocytes (iPSC-CM) and to exacerbate the
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phenotype of familial cardiomyopathy(Davis et al., 2016; Ronaldson-Bouchard et al., 2018), the
corrosive damage and contamination to the tissues impede further incubation after pacing, thus
further studies cannot be done on the same sample. Therefore, using an optogenetic approach can
allow the cardiac tissue being paced by light and avoid the damages mentioned before.

Channelrhodopsin is a light-gated ion channel on cell membranes. The natural form of it is
controlled by blue light, and when the all-trans-retinal in the channelrhodopsin absorbs blue light,
a conformational change will happen as all-trans-retinal becomes 13-cis-retinal. This
conformational change will lead to a further change happen in the transmembrane protein, which
will open up a pore on the membrane and allow an influx of ions. After milliseconds, the 13-cisretinal will shift back to all-trans-retinal, and the pore will be closed to stop the flow of ions(Nagel
et al., 2003). Because the blue light may be toxic to human cells, a red-shift channelrhodopsin
(ReaChR) has been used in recent studies(Lin, Knutsen, Muller, Kleinfeld, & Tsien, 2013).
ReaChR can be excited by orange or red light, and has a higher membrane trafficking, higher
photocurrents, and faster kinetics than channelrhodopsin-2. In addition, the red light will be
absorbed less into blood comparing to the blue light(Lin et al., 2013).

It is notably challenging to deliver the ReaChR directly into cardiac tissue because several barriers
need to be overcome to reach the nucleus. From the outside, ReaChR needs to go through
endothelial barrier, extracellular matrix, and cell membrane before reaching the nucleus [16]. The
current method of delivering ReaChR into the human heart or iPSC-derived bioengineered cardiac
tissue is by virus infection [14]. Although viral delivery has a higher transfection efficiency and a
longer half-life comparing to the non-viral approaches, there is a risk of cytopathic effects, multiple
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insertion sites, and mutagenesis [15]. Plasmid delivery has a simple production process, but
because DNA needs to go through both cell and nucleus membrane to be expressed, the
transfection rate is low and it is less effective in non-proliferating cells, meaning it may not work
in tissues(Al-Dosari & Gao, 2009). To find the delivery method that is safe and efficient, modified
mRNA is used as the gene delivery vehicle.

Modified mRNA (mmRNA) is a chemically modified messenger RNA that allows the gene to be
expressed by cells. Unmodified mRNA will be recognized by the innate immune system in the
endosome, and the protein synthesis will be shut down and eventually cause cell death(Karikó,
Buckstein, Ni, & Weissman, 2005). The modification is done by substituting uridine with
pseudouridine and cytosine with 5-methyl-cytosine during in vitro transcription, and the
modification can help avoid the attack from the immune system, and therefore allow the protein
to be synthesized and expressed in the host cell(Karikó et al., 2005; Kariko, Muramatsu, Ludwig,
& Weissman, 2011).

The goal of this study is to develop a safe and efficient method to control the beating of the in vitro
cardiac tissue that allows the tissue to be used repeatedly in multiple experiments, and eventually
serve to help further understanding of the mechanisms of arrhythmia and finding better solutions
using the iPSC-derived micro heart muscle (µHM) previously developed(Huebsch et al., 2016).
To improve the transfection result, the reducible polycation (RPC) is used as a transfection reagent
of the nucleic acids(Read et al., 2005). The previous study has shown that by coating the nucleic
acids with positive charges, the histidine-rich RPC helped improve the transfection efficiency in
cells since it can be cleaved by the intracellular reducing environment, which allows the better
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release of nucleic acids and lower toxicity(Read et al., 2005). In this study, the RPC is used as the
transfection reagent to improve the transfection of ReaChR plasmids and mmRNAs into tissues.
This study also shows the possibility to use mmRNA to control other properties of the cell with
the gene delivery methods and mmRNA synthesized procedure developed here that help the
investigation of other aspects of heart diseases.

5
Chapter 2: Materials and Methods
In this chapter, the materials and methods used for tissue pacing and gene delivery are described.
Three main methods (lentivirus, plasmids, modified mRNA) applied for gene delivery into micro
tissues are elaborated. The preparation of plasmids, modified mRNA and the transfection reagent
is also included.
Micro Tissue Formation with PDMS Stencils
The dogbone PDMS stencils were first absorbed and disinfected onto a 24-well plate or a 12-well
plate with three dogbones per well prior to the tissue formation, and then treated with Pluronics
F68 and Fibronectin for better cell adhesion(Huebsch et al., 2016). The iPSC was differentiated
into cardiomyocytes by manipulating the Wnt signal following a previously modified
protocol(Huebsch et al., 2016; Lian et al., 2013). After differentiation, the iPSC-CMs were
singularized using 0.25% trypsin and then combined to a final density of 1

10 cells/mL in

EB20 media (Dulbecco’s Modified Eagle Medium with 20% fetal bovine serum) with 10µM
Y27632 and 150µg/mL L-ascorbic acid. The iPSC-CMs were then seeded into a dogbone PDMS
stencil with 2µL of the cell/media mixture given a final concentration of 2

10 cells per

dogbone. The plate was then being centrifuged to get the cells into the dogbone stencils, and then
the wells were filled with EB20/Y27632/ascorbic acid media. On the next day, when the cells
started beating, they were fed with RPMI/B27/ascorbic acid media, and the cells were fed every
other day until the micro tissues were formed.

C2C12 tissues were formed based on a similar protocol. The C2C12 fibroblast was singularized
using 0.05% Trypsin, and then they were suspended into Dulbecco’s Modified Eagle Medium
(DMEM) with 20% fetal bovine serum (FBS) to a density of 1

10 cells/mL, and seeded to the
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dogbone stencils with 5µL per dogbone, given a final density of 5

10 cells per dogbone. The

cells were fed with DMEM with 20% FBS. The cells were compacted inside of the dogbone
stencils and the tissues were formed around day 4 after cell seeding.

C2C12 Myotube Differentiation
The C2C12 myotubes were differentiated from wild type C2C12 fibroblasts based on a previous
protocol(Asano, Ishizuka, Morishima, & Yawo, 2015). On day 0, the C2C12 cells was seeded at a
density of 5

10 cells/well for 48-well plate in culture media (DMEM with 20% FBS). On day

1, when the cells reached around 80% confluency, transfect the cells with desired plasmid. The
transfection result was observed and imaged on the next day, and after confirming the success of
transfection, change culture media into differentiation media (DMEM with 5% horse serum), and
the media was changed every other day. Observe the morphology of the cells everyday until the
C2C12 myotubes formed.
Plasmid Cloning and Modified mRNA synthesis
The ReaChR protein was obtained from pLenti-ReaChR-citrine (Addgene plasmid # 50956 ;
http://n2t.net/addgene:50956 ; RRID:Addgene_50956)(Lin et al., 2013). In order to have the
plasmids expressed in human cells, the Ef1α promoter was fused into the plasmid using the InFusion Cloning kit (Takara #638920) to replace the hSyn promoter. The ReaChR-citrine portion
was also fused into GenII plasmid (Cloned by Tim Rand in the lab of Shinya Yamanaka (Warren
et al., 2010)) using In-Fusion Cloning, and the T7 promoter and PolyA tail in the plasmid allowed
it to be a DNA template for in vitro transcription to synthesize modified mRNA (mmRNA). The
Citrine is a signaling protein to allow the visualization of the transfection. The LifeAct GFP was
also fused into the GenII plasmid to serve as a DNA template for GFP mmRNA.
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The mmRNA synthesis process was modified based on a previous protocol using the MEGAscript
T7 transcription kit (Thermo Fisher, cat. AM1334), murine RNAse inhibitor (NEB, cat. M0314S),
5-Methylcytidine-5′-triphosphate (Me-CTP; Trilink, cat. no. N1014), Pseudouridine-5′triphosphate (Pseudo-UTP; Trilink, cat. no. N1019), vaccinia capping system (NEB cat. M2080S),
and mRNA Cap 2´-O-Methyltransferase (NEB cat. M0366S)(Mandal & Rossi, 2013). The
plasmids were first digested into linear DNA, and the reaction was set up for in vitro transcription
as follow:
Amount Component
To 20 ulNF H2O
2 ul

GTP Solution

2 ul

ATP Solution

1.5 ul

Me-CTP

1.5 ul

Pseudo-UTP

2 ul

10x Reaction Buffer

0.8 ug Linearized DNA
2 ul

Enzyme

After incubation for 4 hours at 37 °C, 1µL of TURBO DNase was added and further incubated for
15 minutes at 37 °C to digest the residual DNA template. After the incubation, the phenolchloroform extraction was done to clean up the synthesized RNA. Before capping the RNA, 10µg
uncapped RNA was combined with nucleus free water to a final volume of 13.5 µL, and they were
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heated at 65 °C for 5 minutes and then paced on ice for another 5 minutes to denature the uncapped
RNA. The reaction was then set up for enzymatic capping as follow:
AmountComponent
13.5 ul Denatured uncapped RNA
2 ul

10x Capping Buffer

1 ul

GTP (10 mM)

1 ul

SAM (4 mM, dilute 32 mM stock to 4 mM)

0.5 ul

Murine RNase Inhibitor

1 ul

Vaccinia Capping Enzyme (10 U/ul)

1 ul

mRNA Cap 2'-O-Methyltransferase (50 U/ul)

The reaction was done by 60 minutes incubation at 37 °C. Another phenol-chloroform extraction
was done to clean up the capped RNA and to obtain our final product of mmRNA. The
concentration of the mmRNA was measured by NanoDrop spectrophotometer. As a positive
control, CleanCap EGFP mRNA (TriLink, cat. L-7201) was used for transfection.
Reducible Polycations Preparation
The Reducible Polycation (RPC) was prepared based on a previous study by Read et al(Read et
al., 2005). The polycondensation reaction was done with 2 mg CH6K3H6C monomer into 150 µL
phosphate-buffered saline (PBS) containing 30 vol% DMSO. The reaction was performed at room
temperature for 48 hours with the solution was continuously being gently shaken on a vortex mixer.
After the reaction was done, the RPCs were purified from DMSO and cyclic by-products using
centrifugal ultra-filters with molecular weight cut-off 10,000. The concentration of RPCs was
measured by BCA assay using the BCA Protein Assay kit (Thermo Fisher, cat. 23227). Finally,
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the RPCs were filter sterilized (0.2µm) and stored at 4 °C. The gel-shift assay was done to exam
the functionality of RPC. The RPCs were combined with Plasmid DNA and incubated for 30
minutes, and then the polyplexes were run on the gel at 135 volts for 15 minutes.
Cell and Tissue Transfection
For cell transfection, the C2C12 cells were seeded to a 48-well plate at 2.5

10 cells per well a

day before the transfection. Right before transfection, the plasmid or mmRNA was diluted into
Opti-MEM (Thermo Fisher, cat. 31985088) to a final concentration of 50 µg/mL, and then the
RPC was added with desired weight ratios of RPC/nucleic acid and the mixture was mixed well
by gently pipetting the solution up and down. The polyplexes were formed by incubation at room
temperature of the solution for 15-30 minutes. After incubation, the polyplexes were added directly
into the culture media drop by drop, and the plate was being rocked gently to enable even
distribution of nucleic acids. The amount of nucleic acids added were 0.5 µg plasmids per well
and 0.25 µg mmRNA per well, and each well was seeded with 2.5

10 cells. As a positive

control, the commercial reagent, Lipofectamine 3000 (Thermo Fisher, cat. L3000001), was used
for plasmid transfection, and TransIt-mRNA (Mirus, cat. MIR2225) was used for mmRNA
transfection. For tissue transfection, both C2C12 tissues and iPSC-CM micro tissues have three
tissues per well, and the ratio of the amount of nucleic acid delivered over the numbers of cells
seeded was tested with the same ratio of cell transfection and double the ratio. Around 18 hours
after mmRNA transfection and around 26 hours after plasmid transfection, the cells and tissues
were imaged to get the transfection result using Nikon microscope. The transfection efficiency
was quantified using Matlab by finding the number of cells expressing the signaling protein and
the overall number of cells.
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Chapter 3: Results of Modified mRNA Synthesis and Gene Delivery
This chapter provides the results of modified mRNA synthesis and gene delivery into
tissues. The transfection efficiency in cells and tissues using plasmids and modified mRNA are
analyzed and compared. The gene delivery results of C2C12 tissues and iPSC-derived micro heart
muscles with the use of reducible polycation are also compared.
Expression of Synthesized ReaChR mmRNA in C2C12 Cells
The synthesized ReaChR mmRNA and LifeAct GFP mmRNA were transfected into C2C12 cells,
and the transfection result is shown (Figure 1). The signal proteins are showing green under GFP
for EGFP mRNA, LifeAct GFP mmRNA, and ReaChR mmRNA, and they are showing the shape
of the C2C12 cells (Figure 1A-C). Comparing to the images showing the nucleus of the cells
(Figure 1D-F), most of the cells are expressing the delivered proteins, indicating that the
synthesized mmRNA has a high transfection efficiency, and the toxicity to cells is limited.

Figure 1. The result of mmRNA shows the successful synthesis of mmRNA, the high
transfection efficiency of mmRNA, and the limited toxicity to cells. (A-C) Images showing the
transfection result of EGFP mRNA, GFP mmRNA, and ReaChR mmRNA respectively, and
green is the expressing protein, proves the cell is transfected. (D-F) Red is the nucleus of C2C12
cells, showing the total amounts of cells of each condition in the same order.
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Application of RPC on Plasmid Delivery and mmRNA Delivery
RPC was proved to be functioning by gel-shift assay (Figure 2). The assay was done with different
weight ratios of RPC over Plasmid DNA, and as the ratio increases, less free Plasmid DNAs are
released in the gel, proving that the RPC has capsulated the plasmids. The transfection of Plasmid
DNA into C2C12 cells using RPC showed a higher transfection rate comparing to the commercial
reagent (Figure 3). The imaging results showed the C2C12 cells are transfected successfully with
GFP plasmids using both Lipofectamine 300 and RPC (Figure 3B-I), where RPC greatly improves
the transfection efficiency. The images are showing the transfection results of Lipofectamine 3000
(Figure 3B, F), RPC/DNA w/w 100 (Figure 3C, G), RPC/DNA w/w 200 (Figure 3D, H), and
RPC/DNA w/w 300 (Figure 3E, I). The best efficiency happened at the RPC/DNA weight ratio
of 300, and the transfection rate is around 20% while the transfection rate with Lipofectamine 3000
is around 8% (Figure 3A). Therefore, we can conclude that RPC doubles the transfection
efficiency of Plasmid DNA delivery into cells comparing to using Lipofectamine 3000.

However, RPC failed to improve the transfection of mmRNA delivery into C2C12 cells comparing
to the commercial reagent, TransIt (Figure 4). The transfection rate was quantified using Matlab
and calculated by GFP expressing cells (Figure 4B-E) over overall cell numbers (Figure 4F-I).
Comparing the transfection rate of EGFP mRNA, it is clear that RPC has a lower transfection
efficiency given that the transfection rate of TranIt is around 60%, and the RPC is around 30%
(Figure 4A).

The images are showing the transfection results of TransIt (Figure 4B, F),

RPC/RNA w/w 40 (Figure 4C, G), RPC/RNA w/w 80 (Figure 4D, H), and RPC/RNA w/w 160
(Figure 4E, I). Comparing the results of Plasmid DNA delivery and mmRNA delivery, mmRNA
has a significantly higher transfection rate than plasmids. As for iPSC-CMs, the RPC with
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RPC/RNA w/w ratio of 40 seems to improve the transfection efficiency of EGFP mRNA delivery
comparing to TransIt, but the difference is not significant (Figure 5).

Figure 2. The gel-shift assay showed that the Plasmid DNA is encapsulated inside the RPC as
less free plasmids are released as the RPC/DNA weight ratio increased.

Figure 3. The result of Plasmid DNAs transfection shows RPC as transfection reagent improves
the transfection efficiency. (A) Comparing the percentage of transfection, RPC has a better
transfection rate than Lipofectamine 3000, and the best result is at RPC/DNA w/w ration of 300.
(B-E) The green indicating transfected cells expressing GFP, and the imaging results of
Lipofectamine 3000 and RPC/DNA w/w ratio of 100, 200, 300 respectively show the C2C12
cells expressing GFP, and (F-I) red shows the nucleus of the cells. (** indicated P < 0.005)
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Figure 4. The result of EGFP mRNA transfection into C2C12 cells shows RPC as transfection
reagent gives lower transfection efficiency comparing to TransIt (A) Comparing the percentage
of transfection, RPC has a lower transfection rate than TransIt, which is 60% and the best result
of RPC is at RPC/RNA w/w ration of 40, which is around 30% (B-E) The imaging results of
TransIt and RPC/RNA w/w ratio of 40, 80, 160 respectively show the C2C12 cells expressing
GFP, which is the green, and (F-I) red is the nucleus of the cells, showing the total number of the
cells. (*** means P < 0.001)

Figure 5. The result of EGFP mRNA transfection into iPSC-CM shows RPC as transfection
reagent gives slightly higher transfection efficiency compared to TransIt. (A) 0.5 µg mRNA was
transfected into one well of cardiomyocytes using TransIt reagent. Green is indicating the cells
that are transduced. (B) The same amount of mRNA was delivered into one well of
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cardiomyocytes using RPC with the RPC/RNA w/w ratio of 40. The difference in transfection
rate was not significant.
mmRNA Delivery into C2C12 Tissues and iPSC-CM µHM
After confirming mmRNA and Plasmid DNA can be transfected in cells, they are used to
transfected into tissues directly. In order to find an efficient delivery method, the transfections are
done in C2C12 tissues first. With three tissues per well for a 12-well plate, and each dogbone
seeded with 5

10 cells per dogbone, given 1.5

10 cells per well. The amount of LifeAct

same DNA/cells ratio in the protocol of Lipofectamine 3000. Similarly, the amount of GFP mRNA
was decided to be 1 µg per well. The transfections were done on day 4 or day 5 after cell seeding
when the tissues were fully formed with both conditions of RPC and commercial reagents. The
RPC/DNA w/w ratio was 300 since it has the best transfection rate in cell transfection, and
similarly, RPC/RNA w/w ratio was 40. From the imaging results, RPC has a higher transfection
efficiency in tissues for LifeAct GFP plasmid (Figure 6A-B), but has a lower transfection
efficiency for GFP mRNA (Figure 6C-D). Also, the GFP mRNA has a significantly higher
transfection rate than GFP plasmid, especially the more condensed parts of the tissue indicating
by higher intensity of the red fluorescence from nuclei (Figure 6). It is shown in the images that
at the most condensed part of tissues, the LifeAct GFP plasmid hardly has any expression, but on
the other hand, the EGFP mRNA has a similar level of expression throughout the tissue. This result
indicate that it is hard for Plasmid DNAs to be transfected into intact tissues. Another transfection
doubling the amount of the nucleic acid was done with both Plasmid DNA and mmRNA, but
shows no noticeable increase in transfection rate (data not shown).

The iPSC-CM µHM was transfected with EGFP mRNA and LifeAct GFP Plasmid DNA, but the
expression GFP plasmid can hardly be seen when imaging inside the µHM (data not shown). The
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EGFP mRNA transfection was done with four different conditions, including using TransIt as
transfection reagent with normal ratio of mRNA/cells (Figure 7A), TransIt with double ratio of
mRNA/cells (Figure 7B), RPC with normal ratio of mRNA/cells (Figure 7C), and finally RPC
with double ratio of mRNA/cells (Figure 7D). The results are showing that with doubling the
amount of mRNA transfected, the transfection rate increased, and the RPC has a higher
transfection rate comparing to TransIt. Overall, the transfection using RPC with double ratio of
RPC/RNA has the best outcome regarding of transfection efficiency. This result is inconsistent
with the results from C2C12 tissue transfection, leading to the possibility that cardiomyocytes have
different barriers for Plasmid DNA and mmRNA delivery.

Figure 6. The result of LifeAct GFP plasmid DNA and EGFP mRNA transfection into C2C12
tissues shows mmRNA has a much higher transfection efficiency in tissues than DNA, especially
for the most condensed part. The green indicating the expressing GFP protein, and the red
indicating the cell nucleus. The higher intensity of the red means more condensed of the part of
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the tissue. (A) The quantification result shows that mmRNA has a significantly higher
transfection rate using TransIt comparing to RPC and plasmid transfection, but doubling the
amount of mmRNA has limited effect. (B, F) The GFP plasmids can hardly be expressed in
C2C12 tissues with Lipofectamine 3000. (C, G) The transfection efficiency was slightly
improved by RPC as reagent with RPC/DNA w/w 300, but the plasmid DNA was still hard to get
into the condensed part. (D, H) EGFP mRNA transfection using TransIt has a significantly
higher transfection rate comparing to plasmid DNA, and even the condensed parts have a high
level of cells being transfected. (E, I) mmRNA transfection using RPC with RPC/RNA w/w 40
has a lower transfection rate than using TransIt, but is still much higher than plasmid DNA. (***
means P < 0.001)

Figure 7. The result of EGFP mRNA transfection into iPSC-CM µHM shows RPC as
transfection reagent and with double amount of mRNA delivered gives the best transfection
efficiency. (A) Normal ratio of mRNA/cells, 1 µg per well for 24-well plate and three tissues per
well, were transfected using TransIt reagent. Scattered green dots indicating the cells that are
transduced, and the blurry green background is the GCamp indicating calcium activities. (B)
Double ratio of mRNA/cells, 2 µg per well, were transfected using TransIt reagent. (C) Normal
Ratio of mRNA/cells were transfected using RPC with RPC/RNA w/w 40. (D) Double ratio of
mRNA/cells were transfected using RPC.

17

Figure 8. The red line is the shining of LED light, and the blue line is the beating of iPSC-CM.
The first blue peak is the spontaneous beating of the cardiomyocytes with the first larger peak
being the contraction, and the second lower peak being relaxation. The peaks and frequency of
LED light and cell beating matches, indicating that the cardiomyocytes have a spontaneous
beating, but it follows the frequency of the LED light when the light started to shine.

ReaChR Plasmid Transduced C2C12 Myotubes Pacing
To prove that the ReaChR can be used in cells for optogenetic pacing, the C2C12 fibroblasts were
differentiated into myotubes and reverse transfected with EF1α ReaChR Plasmid DNA using
Lipofectamine 3000. The myotubes started to form starting from day 5 after differentiation, and
the expressing GFP is showing the shape of the myotubes. On day 9, the transduced myotubes
were imaged and paced under TRITC (532nm). As the light shining, the transduced cell twitched
when the light is on (Supplementary video 1). The twitching indicated that the ReaChR is being
expressed in the cell, and can be excited by the light. The myotube diameter was measure using
ImageJ, and the shortest length was when the cell twitched and longest length was when the cell
in relaxation. The contracted length was 12.5 pixels, proving that the cells are twitching and
changing the diameters under the light.
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The ReaChR was also delivered into iPSC-CM using virus transfection. On the next day of the
transfection, the transduced cells were paced by red LED light, and the cells were beating at the
same frequency of the light shining (Supplementary video 2). The frequency of the cardiomyocytes
under the shining LED light was recorded, and the results showed that the frequency of
cardiomyocytes changed from spontaneous beating to match the frequency of LED light (Figure
8) Overall, the pacing results from transduced C2C12 myotubes and virus infected iPSC-CM
indicate that ReaChR can be excited by light and leads to the beating of the cells.
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Chapter 4: Discussion and Conclusion
In this study, we compared the transfection efficiency under different condition using different
transfection reagents. Overall, the mmRNA has a significant higher transfection efficiency
comparing to Plasmid DNAs for both C2C12 cells and tissues. Considering unlike plasmid DNA,
mRNA does not require entering cell nucleus and is effective in non-dividing cells, this result is
reasonable(Leonhardt et al., 2014). Reducible polycations (RPCs) is a lipopolymer that combine
with nucleic acids to give them positive charges, therefore allow them to enter the cell membrane
and to be delivered into the cells. For C2C12 fibroblasts, the RPC improved the cell transfection
efficiency for Plasmid DNAs comparing to the commercial transfection reagent, and the
transfection rate was doubled at the highest when the RPC/DNA w/w ratio was 300. The
improvement in transfection efficiency is consistent with previous study(Read et al., 2005). On the
other hand, RPC did not work well for mmRNA transfection comparing to the commercial reagent,
TransIt, as the transfection rate decreased from 60% to 30% with the RPC/RNA w/w ratio of 40.
Similar results were showed in C2C12 tissues. The RPC helped to improve the transfection
efficiency for Plasmid DNA, but for mmRNA transfection, TransIt has a higher transfection rate.
In addition, the transfection rate was not improved by doubling the ratio of nucleic acids over cells.
The reason of RPC did not work for mmRNA as well as with plasmid DNA may be the difference
in the mechanisms of mRNA transfection and DNA transfection, and may also be the different
sizes of the nuclei acids. In order to find out the exact reason and to make modification on the
transfection process for mmRNA, further researches may be needed.

The transfection of iPSC-CM and iPSC-CM µHM showed slightly different results from C2C12
cells and tissues. Consistently, the plasmid DNA had very limited delivery into both the
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cardiomyocytes and the µHM, and mmRNA has a significantly higher transfection efficiency.
However, using RPC as transfection did improve the transfection efficiency of mmRNA into µHM,
as well as doubling the amount of mmRNA being delivered. The best transfection result of
mmRNA into µHM was using RPC as transfection reagent with RPC/RNA w/w ratio of 40, and
double the ratio of mmRNA/cells. Transfection into iPSC-CM has proven to be harder than
undifferentiated cells as more integral membrane proteins are on the apical membrane, delimiting
the interaction between membrane and transfection reagent, therefore decreasing the transfection
efficiency(Rybakovsky et al., 2019). With this, it is reasonable that the results are not identical
between iPSC-CM and C2C12s.

With the virus transfection into iPSC-CM and the C2C12 myotubes transfection, the results
showed that ReaChR could be expressed and excited by light, leading to optogenetic pacing using
LED light. However, the virus infected cardiomyocytes did not look as healthy as non-transduced
cells, indicating that virus transfection gives a relatively high toxicity to cells. Therefore, it is
important to find a safer, at the same time efficient method for transfection. Comparing to the virus,
mmRNA has lower toxicity to cells, and from the results above, it is relatively efficient compared
to plasmid DNA. The ReaChR mmRNA was synthesized by a two-step process: in vitro
transcription followed by the capping of mRNA. The cell transfection results showed that the
ReaChR mmRNA can be transfected into cells and expressing the protein. The ReaChR mmRNA
was also transduced into iPSC-CM and expressing the signal fluorescence protein, but in order to
pace the transduced cardiomyocytes, further studies are needed.
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Overall, the study supports that ReaChR can be used for optogenetic pacing of cardiac tissues, and
demonstrates a transfection process with high transfection efficiency using mmRNA and RPC as
transfection reagent. It also shows a method of tissue transfection with mmRNA. With the support
from this study, it is possible to control the beating and even other properties of the cells using
mmRNA.
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Chapter 5: Limitations and Future Work
From this study, we have demonstrated the possibility using ReaChR mmRNA to control the cell
beating. However, there are still some limitation we need to overcome to reach the goal. Although
the experiments results showed the success transfection of mmRNA into cells and tissues, those
ReaChR mmRNA transduced cells have not yet been paced with light successfully. One possibility
we are considering is that although mRNA transfection gives a high transfection rate, the
expression of the protein may not be strong enough because mRNA degrades fast in the cells
comparing to plasmid DNA and virus, therefore the amounts of protein being produced may not
be enough to drive the beating of the cardiomyocytes. Another limitation is that the signal protein
of the ReaChR mmRNA is citrine, which is a yellow fluorescence protein, and because of the
GCamp in our iPSC-CM, the citrine is hard to be imaged, thus provides obstacle in transfection
efficiency quantification. Therefore, another fluorescence protein may be used to replace Citrine
in the future as necessary. There is also a concern regarding to the light source for pacing. The
current LED light is not concentrated enough to apply only on one well at a time, and the spread
of the light may decrease the intensity of the light that are delivered into the cells or tissues. To
resolve this problem, a modification on the light source may be needed.
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Appendix A: Plasmid Map of pLenti ReaChR Citrine
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Appendix B: Plasmid Map of Ef1α ReaChR

28
Appendix C: Plasmid Map of GenII ReaChR
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Appendix D: Plasmid Map of GenII LifeAct GFP

